Laboratorios Richmond S.A.C.I.F.

BASE:RICH Stock Report

Market Cap: AR$123.1b

Laboratorios RichmondC.I.F Past Earnings Performance

Past criteria checks 1/6

Laboratorios RichmondC.I.F has been growing earnings at an average annual rate of 36.1%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 34% per year. Laboratorios RichmondC.I.F's return on equity is 13%, and it has net margins of 13.4%.

Key information

36.14%

Earnings growth rate

36.14%

EPS growth rate

Pharmaceuticals Industry Growth12.39%
Revenue growth rate33.96%
Return on equity13.00%
Net Margin13.42%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Laboratorios RichmondC.I.F makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BASE:RICH Revenue, expenses and earnings (ARS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26119,64216,05146,2850
31 Dec 25126,7262,40446,8320
30 Sep 25139,6413,35555,6130
30 Jun 25134,73419,84253,6090
31 Mar 25132,81827,51250,1180
31 Dec 24120,75431,36845,9030
30 Sep 24101,87510,11037,6620
30 Jun 2493,235-3,52235,3710
31 Mar 2487,983-12,60535,3040
31 Dec 2384,989-23,62933,2170
30 Sep 2387,633-11,20734,1430
30 Jun 2376,914-5,30529,2640
31 Mar 2372,10928623,0010
31 Dec 2257,51850917,9350
30 Sep 2245,7783,05510,4660
30 Jun 2248,2793,3278,7160
31 Mar 2236,2241,8996,3250
31 Dec 2132,3661,1525,1100
30 Sep 2119,7272903,6830
30 Jun 2112,6516353,0900
31 Mar 2110,0915842,5150
31 Dec 209,3307342,2180
30 Sep 207,6804862,0110
30 Jun 206,9783191,8730
31 Mar 206,1402351,7010
31 Dec 195,3031591,5120
30 Sep 193,902-841,3390
30 Jun 193,343-2841,2560
31 Mar 193,013-4141,1610
31 Dec 182,795-3321,0650
30 Sep 182,820-3061,0640
30 Jun 182,296-1258830
31 Mar 181,904137060
31 Dec 171,591495880
30 Sep 171,0481002870
30 Jun 179881032640
31 Mar 179121062420
31 Dec 16856952140
30 Sep 16653282150
30 Jun 16568141970
31 Mar 16504121700
31 Dec 1544661540
30 Sep 15407171260

Quality Earnings: RICH has a large one-off gain of ARS8.2B impacting its last 12 months of financial results to 31st March, 2026.

Growing Profit Margin: RICH's current net profit margins (13.4%) are lower than last year (20.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RICH's earnings have grown significantly by 36.1% per year over the past 5 years.

Accelerating Growth: RICH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RICH had negative earnings growth (-41.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.9%).

Return on Equity

High ROE: RICH's Return on Equity (13%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/22 02:22
End of Day Share Price 2026/07/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laboratorios Richmond S.A.C.I.F. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.